Resistance to PARP-Inhibitors in Cancer Therapy

The pharmacological inhibitors of poly(ADP-ribose) polymerase (PARP) family of proteins have shown promising results in preclinical studies and clinical trials as a monotherapy or in combination therapy for some cancers. Thus, usage of PARP-inhibitors (PARPi) in cancer therapy is bound to increase w...

Descripción completa

Detalles Bibliográficos
Autores principales: Montoni, Alicia, Robu, Mihaela, Pouliot, Émilie, Shah, Girish M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583007/
https://www.ncbi.nlm.nih.gov/pubmed/23450678
http://dx.doi.org/10.3389/fphar.2013.00018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583007/
https://www.ncbi.nlm.nih.gov/pubmed/23450678
http://dx.doi.org/10.3389/fphar.2013.00018

Ejemplares similares